Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"
22 августа 2018 г. обновлено: Takeda
Actos Tablets Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"
The purpose of this survey is to determine the onset of new cerebral and cardiovascular events and changes in metabolic syndrome parameters in patients with type 2 diabetes mellitus on long-term pioglitazone (Actos Tablets) treatment.
Обзор исследования
Подробное описание
This is a special drug use surveillance on long-term use of pioglitazone (Actos Tablets) in patients with type 2 diabetes mellitus, designed to determine the onset of new cerebral and cardiovascular events and changes in metabolic syndrome parameters, and to analyze the association between patient baseline characteristics, including any metabolic syndrome-related risk factors, and the onset of new cerebral and cardiovascular events in an exploratory setting.
Participants will be patients with type 2 diabetes mellitus. The planned sample size is 20000.
The usual adult dosage is 15 to 30 mg of pioglitazone administered orally once daily before or after breakfast.
Тип исследования
Наблюдательный
Регистрация (Действительный)
18223
Критерии участия
Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.
Критерии приемлемости
Возраст, подходящий для обучения
От 20 лет до 74 года (Взрослый, Пожилой взрослый)
Принимает здоровых добровольцев
Нет
Полы, имеющие право на обучение
Все
Метод выборки
Невероятностная выборка
Исследуемая популяция
Type 2 diabetes mellitus
Описание
Inclusion Criteria:
- Patients must have type 2 diabetes mellitus and have undergone measurements for all of the following parameters to be included in this survey:
Waist circumference, height, body weight, blood pressure, Haemoglobin A1c (HbA1c), fasting triglyceride, High-density Lipoprotein (HDL)-cholesterol
Exclusion Criteria:
Patients meeting any of the following criteria (1) to (5) will be excluded:
Patients with any contraindications to pioglitazone (Actos Tablets) treatment as specified below:
Cardiac failure, history of cardiac failure, severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, serious hepatic dysfunction, serious renal dysfunction, severe infection, perioperative state, serious trauma, history of hypersensitivity to any ingredients of pioglitazone (Actos Tablets), pregnancy or possible pregnancy
- Patients aged < 20 or ≥ 75 years
- Patients who currently have or have had any of the following: myocardial infarction, angina pectoris, cardiomyopathy, hypertensive heart disease (including left ventricular hypertrophy with cardiac hypofunction*), atrial fibrillation, atrial flutter, valvular disease, aortic dissection, cerebral infarction, cerebral hemorrhage (including subarachnoid hemorrhage). (*Reduced cardiac function is roughly defined as having a brain natriuretic peptide [BNP] ≥ 40 pg/mL.)
- Patients who have taken pioglitazone (Actos Tablets) within 3 months before enrollment in this survey
- Patients who have been enrolled in the candesartan cilexetil (Blopress) special drug use surveillance "hypertension: survey on metabolic equivalents (MetS) (Challenge-MetS)" at each medical institution.
Учебный план
В этом разделе представлена подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.
Как устроено исследование?
Детали дизайна
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Pioglitazone 15 to 30 mg
administered orally once daily before or after breakfast for 3 years.
|
Пиоглитазон таблетки
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of Participants Who Met at Least One New Cerebral and Cardiovascular Events
Временное ограничение: From Baseline, Up to 3 Years
|
Cerebral and cardiovascular events (Macroangiopathy) include the following: Sudden death, Cerebral infarction, Cerebral hemorrhage, Subarachnoid hemorrhage, Acute myocardial infarction, Angina pectoris requiring intervention or hospitalization for treatment, Cardiac failure requiring hospitalization for treatment, Atrial fibrillation, Aortic dissection.
Reported data was frequency of participants who met at least one new cerebral and cardiovascular event throughout this study.
|
From Baseline, Up to 3 Years
|
|
Changes From Baseline in Metabolic Syndrome Parameters (Body Weight) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in body weight as a one of metabolic syndrome parameters and for each gender (male/female).
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Changes From Baseline in Metabolic Syndrome Parameters (Waist Circumference) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in waist circumference as a one of metabolic syndrome parameters and for each gender (male/female).
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Changes From Baseline in Metabolic Syndrome Parameters (Haemoglobin A1c (HbA1c) [National Glycohemoglobin Standardization Program (NGSP)]) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in HbA1c (NGSP) as a one of metabolic syndrome parameters.
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Changes From Baseline in Metabolic Syndrome Parameters (Fasting Blood Glucose) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in fasting blood glucose as a one of metabolic syndrome parameters.
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Changes From Baseline in Metabolic Syndrome Parameters (Fasting Blood Insulin Level) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in fasting blood insulin level as a one of metabolic syndrome parameters.
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Changes From Baseline in Metabolic Syndrome Parameters (Total Cholesterol Level) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in total cholesterol level as a one of metabolic syndrome parameters.
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Changes From Baseline in Metabolic Syndrome Parameters (High-density Lipoprotein (HDL) Cholesterol Level) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in HDL cholesterol level as a one of metabolic syndrome parameters.
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Changes From Baseline in Metabolic Syndrome Parameters (Fasting Triglyceride Level) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in fasting triglyceride level as a one of metabolic syndrome parameters.
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Changes From Baseline in Metabolic Syndrome Parameters (Systolic Blood Pressure) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in systolic blood pressure as a one of metabolic syndrome parameters.
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Changes From Baseline in Metabolic Syndrome Parameters (Diastolic Blood Pressure) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in metabolic syndrome parameters at final assessment point (up to 3 years) were reported.
The reported data on this outcome measure is in diastolic blood pressure as a one of metabolic syndrome parameters.
|
From Baseline and final assessment point (Up to 3 Years)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Changes From Baseline in HbA1c (NGSP) With Number of Metabolic Syndrome-related Risk Factor (MetS-related Factor) at Final Assessment Point
Временное ограничение: From Baseline and final assessment point (Up to 3 Years)
|
Changes from baseline in HbA1c (NGSP) with number of MetS-related factor were reported instead.
Risk factors included Glucose Intolerance, Complication of Hypertension, Complication of Hyperlipidemia, Obesity, and Family History of Diabetes in Second-Degree Relatives.
|
From Baseline and final assessment point (Up to 3 Years)
|
|
Association Between Patient Baseline Characteristics, Including Any Metabolic Syndrome-related Risk Factors, and Onset of New Cerebral and Cardiovascular Events
Временное ограничение: 3 Years
|
3 Years
|
Соавторы и исследователи
Здесь вы найдете людей и организации, участвующие в этом исследовании.
Спонсор
Даты записи исследования
Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.
Изучение основных дат
Начало исследования (Действительный)
16 октября 2007 г.
Первичное завершение (Действительный)
30 июня 2013 г.
Завершение исследования (Действительный)
30 июня 2013 г.
Даты регистрации исследования
Первый отправленный
1 декабря 2013 г.
Впервые представлено, что соответствует критериям контроля качества
1 декабря 2013 г.
Первый опубликованный (Оценивать)
6 декабря 2013 г.
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
24 января 2019 г.
Последнее отправленное обновление, отвечающее критериям контроля качества
22 августа 2018 г.
Последняя проверка
1 августа 2018 г.
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 237-016
- JapicCTI-132328 (Идентификатор реестра: JapicCTI)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
НЕТ
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Нет
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Нет
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .